持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688356 证券简称：键凯科技 公告编号：2025-029 北京键凯科技股份有限公司 大股东持有的基本情况 截至本公告日，北京键凯科技股份有限公司（以下简称"公司"）股 东吴凯庭持有公司股份 9,145,847 股，占公司总股本的 15.08%。上述 股份来源为公司首发前股份，已于 2023 年 8 月 28 日解除限售。 减持计划的主要内容 因股东自身资金需求，吴凯庭计划自本公告披露之日起 15 个交易日后 的 3 个月内通过大宗交易方式减持公司股份不超过 1,213,014 股，拟 减持比例不超过公司总股本的 2%。 本次减持计划的减持价格按市场价格确定。若减持期间公司有派息、 送股、资本公积金转增股本、配股等除权除息事项，减持计划将进行 相应调整。 公司于近日收到股东吴凯庭先生出具的《关于股份减持计划的告知函》，现 将具体情况公告如下： 一、减持主体的基本情况 | 股东名称 | 吴凯庭 | | ...

Group 1 - Key Point 1: JianKai Technology (688356) announced on September 8 that shareholder Wu Kaiti, who holds 15.08% of the shares, plans to reduce his stake through block trading [1] - Key Point 2: The planned reduction will not exceed 1.213 million shares, representing a maximum reduction of 2% of the company's total share capital [1] - Key Point 3: The reduction price will be determined based on market prices [1]

Group 1 - The core point of the article is that JianKai Technology (688356.SH) announced a share reduction plan by shareholder Wu Kaiting due to personal funding needs [1] - Wu Kaiting plans to reduce holdings by no more than 1.213 million shares, which represents up to 2% of the company's total share capital [1] - The reduction will be executed through block trading within three months starting from 15 trading days after the announcement, with the selling price determined by market conditions [1]

Core Viewpoint - Key shareholder Wu Kaiting of JianKai Technology (688356.SH) plans to reduce his stake in the company by up to 1,213,014 shares, representing a maximum of 2% of the total share capital, due to personal funding needs [1] Summary by Relevant Sections - Shareholder Reduction Plan - Wu Kaiting intends to sell shares through block trading within three months after the announcement, starting 15 trading days from the disclosure date [1] - The reduction price will be determined based on market conditions, and adjustments will be made if there are any ex-rights or ex-dividend events during the reduction period [1]

键凯科技公告，股东吴凯庭因自身资金需求，计划自披露起15个交易日后的3个月内，即2025年10月9日 至2026年1月8日，通过大宗交易方式减持公司股份不超过121.3万股，占公司总股本的2%；截至公告日 其持股914.58万股，占15.08%，所持股份来源为IPO前取得。 ...

2025 年 9 月 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议资料 目录 证券代码：688356 证券简称：键凯科技 北京键凯科技股份有限公司 2025 年第一次临时股东大会 会议资料 | 2025 年第一次临时股东大会会议须知 | 3 | | --- | --- | | 2025 年第一次临时股东大会会议议程 | 6 | | 议案一：《关于取消监事会并修订<公司章程>的议案》 8 | | | 议案二：《关于修订和制定部分公司内部管理制度的议案》 | 9 | | 议案三：《关于补选公司独立董事的议案》 | 11 | 2 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议资料 北京键凯科技股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）以及《北京键凯科技股份有限公 司章程》（以下简称"《公司章程》"）和《北京键凯科技股份有限公司股东大会议 事规则》等有关规定，特制定北京键凯科技股份有限公 ...

Group 1 - The innovative drug concept stocks are experiencing significant activity, with Jimin Health hitting the daily limit up [1] - JianKai Technology has seen an increase of over 10% [1] - Other companies such as YueKang Pharmaceutical, NuoSiGe, QianYan Bio, XinLiTai, and Chengdu XianDao are also following the upward trend [1]

Investment Rating - The report maintains a "Buy" rating for the company, considering the significant growth in overseas revenue and the promising application space for its drug and medical device projects [4]. Core Insights - The company is undergoing a performance transformation period, with orderly progress in new drug and medical beauty projects. In H1 2025, the company achieved operating revenue of 130 million yuan, a year-on-year increase of 0.89%, while the net profit attributable to the parent company was 22 million yuan, a decrease of 21.08% [1][4]. - Domestic sales have decreased while exports have increased. The main business revenue remained stable compared to the same period last year, with product sales revenue at 125.56 million yuan, down 0.26% year-on-year, and technical service revenue at 3.78 million yuan, up 83.77% year-on-year. Domestic sales revenue was 20.48 million yuan, down 58.35%, while export revenue was 105.08 million yuan, up 36.96% [2][3]. Summary by Sections Financial Performance - In H1 2025, the company reported a total R&D investment of 42.60 million yuan, an increase of 52.44% year-on-year, with R&D investment accounting for 32.84% of operating revenue, up 11.11 percentage points year-on-year. The company is advancing its clinical trials for new drugs and has received regulatory approvals for its medical beauty devices [3][4]. Profit Forecast and Valuation - The profit forecast for the company remains at 53 million yuan for 2025, 124 million yuan for 2026, and 172 million yuan for 2027. The report highlights the potential for significant growth in overseas revenue and the development of its drug and device pipeline [4][10].

Core Viewpoint - JianKai Technology (688356) reported a revenue increase but a profit decline in its 2025 mid-year financial report, indicating potential challenges in profitability despite stable revenue growth [1] Financial Performance - Total revenue reached 130 million yuan, a year-on-year increase of 0.89% - Net profit attributable to shareholders was 22.05 million yuan, a year-on-year decrease of 21.08% - In Q2, total revenue was 60.62 million yuan, a year-on-year decline of 4.97% - Q2 net profit attributable to shareholders was 10.17 million yuan, a year-on-year decrease of 24.6% [1] Profitability Metrics - Gross margin stood at 59.47%, down 11.42% year-on-year - Net margin was 17.0%, down 21.77% year-on-year - Total selling, administrative, and financial expenses amounted to 28.43 million yuan, accounting for 21.91% of revenue, a decrease of 2.08% year-on-year - Earnings per share were 0.36 yuan, a year-on-year decrease of 21.74% [1] Return on Investment - The company's Return on Invested Capital (ROIC) was 2.25%, indicating weak capital returns - Historical median ROIC since listing is 15.77%, with the worst year being 2024 at 2.25% [2] Debt and Cash Flow - The company has a healthy cash asset position - The operating cash flow per share was 0.13 yuan, a significant year-on-year decrease of 88.23% [3] Accounts Receivable - The accounts receivable to profit ratio reached 276.46%, suggesting potential issues with cash collection [4] Fund Holdings - The largest fund holding JianKai Technology is JinXin Value Selected Mixed A, which has reduced its holdings to 35,400 shares - The fund's current scale is 15 million yuan, with a recent net value increase of 0.55% and a one-year increase of 114.48% [5]

Meeting Overview - The third supervisory board meeting of Beijing Jiankai Technology Co., Ltd. was held on August 27, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1]. Supervisory Board Resolutions - The supervisory board unanimously approved the 2025 semi-annual report, confirming that the report's preparation and review processes adhered to legal and internal regulations, accurately reflecting the company's financial status and operational results [1][2]. - The board also approved the proposal to cancel the supervisory board and amend the company's articles of association, aimed at enhancing corporate governance and aligning with the latest legal requirements [2][3]. - Additionally, the board agreed to the provision for asset impairment for the first half of 2025, stating that this decision aligns with the principle of prudence and relevant accounting standards, ensuring a true and fair representation of the company's financial condition [3].